China-based Hangzhou Celgenyx Gene Technology Co., Ltd has announced the completion of a Series A financing round, raising RMB 100 million (USD 13.68 million). The round was led by Vivo Capital. The proceeds will be directed toward the research and development of Celgenyx’s next-generation off-the-shelf cell therapy.
Current Landscape of Cellular Immunotherapy
Most marketed cellular immune products currently rely on autologous cells, which are reinfused into patients after expansion in vitro. These products typically have a long preparation cycle, relatively higher prices, and a limited scope of application. These factors collectively restrict the wider adoption of cellular immunotherapy.
Celgenyx’s Vision and Strategy
Celgenyx aims to address these limitations by developing a new generation of universal, off-the-shelf, and mass-produced cell therapies. The company’s strategy combines in-house development with global cooperation, targeting the creation of more accessible and scalable solutions for cellular immunotherapy. This approach is expected to significantly broaden the application of cell-based treatments.-Fineline Info & Tech
